Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11

Iomaba -B has completed several physician sponsored clinical trials examining its potential as a bone marrow conditioning regimen for hematopoietic stem cell transplantation in various blood cancers including a phase I/II study in relapsed and/or refractory elderly acute myeloid leukemia patients.

http://www.sys-con.com/node/2857014